Study guide
13.2 Trauma Pharmacotherapy: Massive Transfusion, TXA, Open Fractures, Tetanus & Burns
BCEMP Board Certified Emergency Medicine Pharmacist Exam
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Introduction, Triage, and Resuscitation Fundamentals
1.1 BCEMP Exam Logistics, Content Outlines & Scoring 1.2 Emergency Triage Systems (ESI) & Pre-Hospital Care Coordination 1.3 Resuscitation Pharmacology, Pharmacokinetics & Vascular Access
2 Chapter 2: Cardiac Arrest and Dysrhythmias
2.1 Adult Cardiac Arrest & ACLS Pharmacotherapy Protocols 2.2 Acute Tachyarrhythmias: Narrow- and Wide-Complex Management 2.3 Symptomatic Bradycardia & Vasoactive Chronotropic Support 2.4 Post-Cardiac Arrest Care & Targeted Temperature Management (TTM)
3 Chapter 3: Shock and Hemodynamic Resuscitation
3.1 Sepsis & Septic Shock: Surviving Sepsis Campaign 2026 Resuscitation 3.2 Cardiogenic & Obstructive Shock, Mechanical Circulatory Support & LVADs 3.3 Hypovolemic & Hemorrhagic Shock Fluid Protocols
4 Chapter 4: Airway Management and Rapid Sequence Intubation (RSI)
4.1 Rapid Sequence Intubation (RSI) Process & Pretreatment Agents 4.2 RSI Induction Agents: Pharmacology, Selection & Dosing 4.3 Neuromuscular Blocking Agents & Post-Intubation Analgosedation
5 Chapter 5: Neurocritical Care and Neurologic Emergencies
5.1 Acute Ischemic Stroke: Thrombolysis & Blood Pressure Control 5.2 Intracranial Hemorrhage & Elevated ICP Pharmacotherapy 5.3 Status Epilepticus: Tiered Emergent Anticonvulsant Therapy 5.4 Traumatic Brain Injury & Spinal Cord Emergencies
6 Chapter 6: Acute Coronary Syndromes and Acute Heart Failure
6.1 Acute Coronary Syndromes: STEMI & NSTE-ACS Pharmacotherapy 6.2 Acute Decompensated Heart Failure & Cardiogenic Pulmonary Edema 6.3 Hypertensive Crises: Emergencies, Urgencies & Target Blood Pressure
7 Chapter 7: Pulmonary and Allergic Emergencies
7.1 Acute Pulmonary Embolism: Risk Stratification & Thrombolytic Therapy 7.2 Severe Asthma Exacerbation & COPD Acute Management 7.3 Anaphylaxis & Severe Allergic Reactions: Acute Epinephrine Protocols
8 Chapter 8: Clinical Toxicology: Approach to Poisoning and Common Overdoses
8.1 Approach to the Poisoned Patient: Poison Centers, Toxidromes, Decontamination & Enhanced Elimination 8.2 Acetaminophen Overdose & N-Acetylcysteine Dosing Strategies 8.3 Salicylate Toxicity & Toxic Alcohol Management (Fomepizole) 8.4 Opioid Toxicity & Sedative-Hypnotic/Alcohol Withdrawal Syndromes 8.5 Beta-Blocker & Calcium Channel Blocker Toxicity (HIET, Calcium, Glucagon)
9 Chapter 9: Toxicology: Specialized Poisonings and Antidotes
9.1 Digoxin, Tricyclic Antidepressants & Anticholinergic Toxicity 9.2 Cyanide, Carbon Monoxide & Organophosphate/Cholinergic Toxins 9.3 Snake and Spider Envenomations & Heavy Metal Chelation 9.4 Additional Antidotes: Methemoglobinemia, Isoniazid, Sulfonylureas, Valproate, Sympathomimetics & LAST
10 Chapter 10: Hemostasis, Anticoagulant Reversal, and Hematology
10.1 DOAC & Warfarin Reversal: Specific Reversal Agents & 4F-PCC 10.2 Heparin-Induced Thrombocytopenia (HIT) & Direct Thrombin Inhibitors 10.3 Sickle Cell Vaso-Occlusive Crises & Acute Chest Syndrome
11 Chapter 11: Endocrine, Electrolyte, and Metabolic Emergencies
11.1 Diabetic Ketoacidosis (DKA) & Hyperosmolar Hyperglycemic State (HHS) 11.2 Severe Electrolyte Emergencies: Hyperkalemia & Hyponatremia 11.3 Endocrine Crises: Thyroid Storm, Myxedema Coma & Acute Adrenal Crisis 11.4 Acute Kidney Injury, Dialyzability & Drug Dosing during RRT
12 Chapter 12: Infectious Diseases and Antimicrobial Stewardship
12.1 Severe Community & Hospital-Acquired Infections in the ED 12.2 Skin & Soft Tissue, STI, and Vector-Borne Emergencies 12.3 ED Antimicrobial Stewardship & Rapid Microbiologic Diagnostics
13 Chapter 13: Special Populations: Pediatrics, Trauma, and Obstetrics
13.1 Pediatric Resuscitation, Status Epilepticus & PALS Pharmacotherapy 13.2 Trauma Pharmacotherapy: Massive Transfusion, TXA, Open Fractures, Tetanus & Burns 13.3 Obstetric & Gynecologic Emergencies: Preeclampsia, Eclampsia & PPH
14 Chapter 14: Medication Safety, ED Operations, and Disaster Preparedness
14.1 ED High-Alert Medications, Error Reporting & Technology Safeguards 14.2 ED Workflow, Transitions of Care & Boarding Patient Management 14.3 Mass Casualty Incidents, CBRNE Countermeasures & Strategic Stockpiles
15 Chapter 15: Biostatistics, Study Design, and Literature Evaluation
15.1 Biostatistics & Hypothesis Testing: Power, Errors & Interpretations 15.2 Clinical Study Designs & Measures of Effect 15.3 Literature Evaluation, Clinical Guidelines & Research Conduct in the ED
16 Chapter 16: Medical Devices, Ventilation, and Medication Delivery
16.1 Mechanical Ventilation, Noninvasive Ventilation & High-Flow Oxygen: What the Pharmacist Must Know 16.2 Vascular Access, Enteral Tubes, Drains & Extravasation Management 16.3 Infusion Pumps, Patient-Owned Devices & Medication Delivery Device Counseling
17 Chapter 17: Organ-System Emergencies: GI, GU, Oncology, Neurology, ENT, Pain, and Psychiatry
17.1 Gastrointestinal & Hepatic Emergencies: GI Bleeding, Cirrhosis Complications, Pancreatitis & Vomiting 17.2 Genitourinary Emergencies: UTI & Pyelonephritis, Renal Colic, Urinary Retention, Priapism & Scrotal Infections 17.3 Oncologic, Immunotherapy & Hematologic Emergencies: Febrile Neutropenia, TLS, Hypercalcemia, irAEs, CAR-T, Hemophilia & TTP 17.4 Headache & Neuromuscular Emergencies: Migraine, Cluster, Myasthenic Crisis, Guillain-Barré & Bell's Palsy 17.5 Ophthalmologic, ENT & Dental Emergencies: Eye Injuries, Angle Closure, Angioedema, Epistaxis, Ear & Throat Infections and Dental Pain 17.6 Acute Pain Management & Procedural Sedation and Analgesia in the ED 17.7 Psychiatric Emergencies: Severe Agitation, Serotonin Syndrome, NMS, Lithium Toxicity & Psychotropic Overdose
18 Chapter 18: Special Populations, Medication Access, and Professional Practice
18.1 Pharmacogenomics, Adverse Drug Events & High-Risk Drug Interactions in Emergency Care 18.2 Special Populations: Older Adults, Extremes of Weight, Pregnancy & Lactation, and Immunocompromised Patients 18.3 Social Determinants of Health, Health Literacy & Medication Access at ED Discharge 18.4 Healthcare Regulations & Standards: FDA, REMS, Bar Coding, DEA, CMS, EMTALA, The Joint Commission, NIOSH & USP 18.5 Formulary & Inventory Management, Drug Shortages, Antidote Stocking & Clinical Decision Support 18.6 Quality Improvement, Practice Standards & Interprofessional Collaboration (Protocols, Teamwork & Debriefing)
13.2 Trauma Pharmacotherapy: Massive Transfusion, TXA, Open Fractures, Tetanus & Burns
Key Takeaways Explain This Topic AI
Damage Control Resuscitation (DCR) prioritizes permissive hypotension (target SBP 80-90 mmHg, MAP 50-65 mmHg in non-TBI patients), restricts crystalloids, and delivers balanced 1:1:1 blood component therapy (PRBCs, FFP, and platelets), which the landmark PROPPR trial validated reduces 24-hour exsanguination mortality.
Tranexamic acid (TXA) must be initiated within 3 hours of traumatic injury (1 g IV over 10 min followed by 1 g IV infusion over 8 hours); starting it more than 3 hours after injury increased death due to bleeding in CRASH-2.
Open fractures need antibiotics within 1 hour (cefazolin for Gustilo types I–II, ceftriaxone for type III, plus penicillin for farm or fecal contamination), and contaminated wounds need tetanus toxoid if 5 or more years have passed, plus TIG when the vaccine history is incomplete.
Citrate in transfused blood components chelates ionized calcium, precipitating severe hypocalcemia and blunting the clotting cascade; proactive empiric calcium repletion (1 g calcium chloride or 3 g calcium gluconate per 4 units of blood products) is mandatory.
Acute thermal burn fluid requirements are calculated using modified Brooke/Parkland formulas (2-4 mL x kg x % TBSA Lactated Ringer's), delivering 50% within the first 8 hours post-injury and titrating strictly to an adult urine output of 0.5 mL/kg/h to avoid fatal fluid creep.
Last updated: October 2026
13.2 Trauma Resuscitation, Hemorrhage Control & Acute Burn Management
Note
Independent BCEMP study resource provided by ExamFinch. Content is organized around emergency medicine pharmacotherapy principles tested on clinical specialist certification examinations.
Damage Control Resuscitation (DCR) & The Lethal Diamond
Severe traumatic injury induces a rapid, life-threatening derangement historically termed the Lethal Triad : Hypothermia (<35°C, which suppresses coagulation enzyme kinetics), Acidosis (pH <7.2, which drastically reduces thrombin generation), and Coagulopathy (driven by consumption, hyperfibrinolysis, and endothelial disruption). Modern emergency resuscitation expands this concept to the Lethal Diamond by recognizing Hypocalcemia as an independent, life-threatening fourth component.
Core Tenets of Damage Control Resuscitation
Immediate Hemorrhage Control : Rapid surgical or endovascular intervention to arrest mechanical bleeding.
Permissive Hypotension : Maintaining a subnormal blood pressure target ( systolic BP 80 to 90 mmHg or mean arterial pressure 50 to 65 mmHg ) until surgical hemostasis is achieved. This prevents "popping the clot"—the mechanical dislodgement of newly formed, fragile hemostatic plugs caused by hydrostatic pressure surges. Contraindication : Permissive hypotension is strictly contraindicated in patients with severe Traumatic Brain Injury (TBI) , where a minimum SBP ≥100 to 110 mmHg is required to maintain cerebral perfusion pressure (CPP ≥60 mmHg).
Minimization of Crystalloids : Restricting isotonic crystalloid infusions (0.9% normal saline or Lactated Ringer's). Large crystalloid volumes induce dilutional coagulopathy, hypothermia, endothelial glycocalyx degradation, and hyperchloremic metabolic acidosis.
Balanced Component Therapy : Resuscitating with blood products in fixed physiological proportions that mimic reconstituted whole blood.
Massive Transfusion Activation & Whole Blood
A Massive Transfusion Protocol (MTP) is activated for life-threatening hemorrhagic shock, for example an Assessment of Blood Consumption (ABC) score of 2 or more (penetrating mechanism, SBP 90 mmHg or less, heart rate 120 bpm or more, positive FAST). Section 3.3 covers the evidence for balanced 1:1:1 ratios (PROPPR) and viscoelastic-guided replacement. In trauma practice, the pharmacist's added tasks are:
Product sequencing : MTP coolers typically deliver 6 units of red cells, 6 units of plasma and 1 apheresis platelet pack, repeated until hemostasis.
Low-titer group O whole blood (LTOWB) : increasingly stocked by trauma centers and EMS. It delivers red cells, plasma and platelets in one unit with less additive volume.
Anticoagulant history : identify warfarin, DOAC or antiplatelet use at arrival and start reversal in parallel with transfusion (see Section 10.1).
Hypothermia prevention : warm every product and fluid.
Tranexamic Acid (TXA): CRASH-2 & CRASH-3 Timing Windows
Tranexamic acid (TXA) is a synthetic lysine-analogue antifibrinolytic that reversibly blocks the lysine-binding sites on plasminogen molecules, preventing its conversion to plasmin and halting the enzymatic degradation of fibrin clots.
Dosing Protocol
Loading Dose : 1 g IV infused over 10 minutes (rapid undiluted IV push must be avoided to prevent transient drug-induced vasodilation and hypotension).
Maintenance Infusion : 1 g IV continuous infusion administered over 8 hours .
The 3-Hour Therapeutic Imperative (CRASH-2)
The landmark CRASH-2 trial (20,211 trauma patients with significant hemorrhage) proved that TXA significantly reduces all-cause mortality (RR 0.91) and risk of death due to bleeding (RR 0.85). Subgroup analysis revealed an absolute dependency on the timing of drug administration:
Initiated within 1 hour of injury : Greatest survival benefit; reduces risk of death from bleeding by 32% (RR 0.68, 95% CI 0.57-0.82).
Initiated between 1 and 3 hours of injury : Significant survival benefit; reduces risk of death from bleeding by 21% (RR 0.79, 95% CI 0.64-0.97).
Initiated >3 hours post-injury : HARMFUL AND CONTRAINDICATED . TXA started more than 3 hours after injury was associated with a statistically significant increase in death due to bleeding (RR 1.44, 95% CI 1.12–1.84). CRASH-2 found no overall increase in vascular occlusive events with TXA.
Warning
Pathophysiologically, acute trauma triggers an immediate, transient state of hyperfibrinolysis. By 3 to 6 hours post-injury, trauma-induced coagulopathy naturally transitions into fibrinolytic shutdown characterized by microvascular thrombosis, tissue ischemia, and multiorgan failure. Administering an antifibrinolytic during late fibrinolytic shutdown accelerates microvascular occlusion and worsens mortality. Never initiate TXA in trauma patients presenting >3 hours after injury .
Traumatic Brain Injury (CRASH-3)
The CRASH-3 trial evaluated TXA in patients with acute traumatic brain injury presenting within 3 hours of injury with GCS ≤12 or intracranial hemorrhage on CT. TXA reduced head injury-related mortality specifically in patients with mild-to-moderate TBI (GCS 9-15) (RR 0.78, 95% CI 0.64-0.95), while showing no benefit in catastrophic, un-survivable severe TBI (GCS 3 or unreactive pupils).
- Open Fractures, Tetanus Prophylaxis & Trauma Analgesia
- Open Fracture Antibiotics
Early antibiotics are the most important modifiable factor in preventing deep infection after an open fracture. Give the first dose within 1 hour of arrival . The ACS TQIP best-practice guidance is a common reference:
Gustilo-Anderson type Typical empiric regimen Notes
Type I–II (wound under 10 cm, moderate contamination) Cefazolin 2 g IV (3 g if 120 kg or more) every 8 hours Clindamycin for severe beta-lactam allergy
Type III (extensive soft-tissue injury, heavy contamination) Ceftriaxone 2 g IV daily (or cefazolin plus an aminoglycoside in older protocols) Gram-negative coverage for heavy contamination
Farm, soil or fecal contamination Add penicillin (or ampicillin) for clostridia Water exposure may need fluoroquinolone or doxycycline coverage
Continue for about 24 hours after definitive wound closure (longer, often up to 72 hours, for type III).
Tetanus Prophylaxis (CDC/ACIP)
- Wound 3 or more prior doses Fewer than 3 doses or unknown
- Clean, minor Tdap or Td if 10 years or more since the last dose Tdap/Td vaccine; no TIG
All other wounds (dirty, puncture, burns, crush) Tdap or Td if 5 years or more since the last dose Tdap/Td vaccine plus tetanus immune globulin (TIG) 250 units IM at a separate site
Prefer Tdap for adults who have never received it. Patients with HIV or severe immunosuppression and a contaminated wound should receive TIG regardless of their vaccination history.
Trauma Analgesia
Hemodynamically fragile patients : small titrated doses of fentanyl (about 0.5 to 1 mcg/kg) or sub-dissociative ketamine (0.1 to 0.3 mg/kg IV) preserve blood pressure better than morphine.
Regional anesthesia : a fascia iliaca or femoral nerve block for hip fracture, and serratus anterior or erector spinae blocks for rib fractures, reduce opioid needs and delirium in older adults. Know the local anesthetic maximum doses (Section 9.4).
NSAIDs : avoid in active hemorrhage, acute kidney injury and early after major surgical fixation. Acetaminophen is a safe baseline.
Citrate Toxicity & Proactive Calcium Repletion
All commercial blood products are anticoagulated with citrate (sodium citrate/citric acid), which prevents in vitro coagulation by chelating extracellular ionized calcium (coagulation Factor IV).
Pathophysiology
Under normal physiological conditions, circulating citrate is rapidly metabolized into bicarbonate by hepatic and renal pathways. During massive blood transfusion, large volumes of citrate overwhelm hepatic metabolic capacity, compounded by shock-induced hepatic hypoperfusion and hypothermia. Circulating citrate rapidly chelates endogenous ionized calcium (Ca²⁺) and magnesium (Mg²⁺).
Clinical Sequelae
Coagulopathy : Tenase and prothrombinase complex assemblies are strictly calcium-dependent. Hypocalcemia severely inhibits thrombin generation.
Myocardial Depression : Calcium is required for myocardial excitation-contraction coupling. Severe hypocalcemia produces refractory hypotension, reduced stroke volume, and decreased left ventricular ejection fraction.
Electrophysiological Instability : Marked prolongation of the QT interval , ST-segment lengthening, and heightened vulnerability to polymorphic ventricular arrhythmias and asystole.
Mandatory Proactive Calcium Repletion
Waiting for laboratory calcium results during an active MTP leads to severe, preventable cardiac arrest. Empiric, proactive calcium administration is mandatory:
Administration Trigger : Administer 1 g IV Calcium Chloride OR 3 g IV Calcium Gluconate for every 4 units of blood products transfused (or after the completion of the first MTP cooler).
Salt Selection : Calcium chloride provides three times more elemental calcium than calcium gluconate (1 g calcium chloride = 13.6 mEq [6.8 mmol] Ca²⁺; 1 g calcium gluconate = 4.65 mEq [2.3 mmol] Ca²⁺). Both salts ionize rapidly, with no hepatic step needed. Calcium chloride delivers more calcium per syringe in critical shock, but it must be administered via central venous access or a well-running, large-bore peripheral catheter due to the risk of severe tissue necrosis if extravasated.
Resuscitation Target : Maintain ionized calcium (iCa) >1.1 to 1.2 mmol/L throughout the resuscitation.
Acute Thermal Burn Resuscitation & Fluid Titration
Thermal burn injuries involving ≥20% Total Body Surface Area (% TBSA) trigger massive systemic capillary leak, endothelial damage, and third-space fluid sequestration ("burn shock").
Burn Size Estimation: Adult Rule of Nines
Only second-degree (partial-thickness) and third-degree (full-thickness) burns are included in % TBSA calculations; first-degree erythema (superficial sunburn) is excluded:
- Head and Neck : 9% total (4.5% anterior, 4.5% posterior)
- Anterior Torso (Chest and Abdomen) : 18%
- Posterior Torso (Upper and Lower Back) : 18%
- Each Upper Extremity : 9% total (4.5% anterior, 4.5% posterior; both arms = 18%)
- Each Lower Extremity : 18% total (9% anterior, 9% posterior; both legs = 36%)
- Perineum / Genitalia : 1%
(For scattered or irregular burns, the patient's palmar surface including closed fingers equals ~1% TBSA) .
Fluid Calculation: Parkland & Modified Brooke Formulas
Resuscitation is performed using balanced crystalloids ( Lactated Ringer's is the fluid of choice; normal saline is avoided due to the induction of severe hyperchloremic metabolic acidosis):
Parkland Formula : 4 mL × Weight (kg) × % TBSA burned over 24 hours
Modified Brooke / American Burn Association (ABA) Consensus : 2 mL × Weight (kg) × % TBSA burned over 24 hours (for thermal burns; 4 mL/kg/% TBSA is reserved for electrical burns with myoglobinuria).
Resuscitation Timeline & Administration Schedule
First 8 Hours : 50% of the total calculated 24-hour volume must be infused within the first 8 hours calculated from the EXACT TIME OF INJURY , not the time of hospital arrival. Any fluid volume infused prior to arrival is subtracted from this 8-hour total.
Remaining 16 Hours : The remaining 50% of the calculated volume is infused evenly over the subsequent 16 hours.
Dynamic Titration & Avoiding "Fluid Creep"
Formulas provide only an initial starting estimate. Administering excessive fluid volumes causes "fluid creep" , predisposing the patient to pulmonary edema, extremity compartment syndromes requiring escharotomies, and fatal Abdominal Compartment Syndrome (ACS) .
Important
Crystalloid infusion rates must be titrated up or down by 20% to 30% every hour based strictly on physiological endpoints:
Adult Target Urine Output : 0.5 mL/kg/hour (approximately 30 to 50 mL/hour ).
Pediatric Target Urine Output (<30 kg) : 1.0 mL/kg/hour .
In high-voltage electrical injuries with pigmenturia (myoglobinuria), titrate fluids to a target urine output of 1.0 to 1.5 mL/kg/hour until the urine clears.